Adverse effects · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRM197‐PCV7in low‐risk infants OMPC‐PCV7in low‐risk infants PHiD‐PC10 and PHiD‐PC11 in low‐risk infants CRM197‐PCV7/9 and CRM197‐PCV7 plus TIVin older children · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Seizure freedom · children (aged 1 to 18 years) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes seizure freedom (100% reduction in seizure frequency) compared with usual care (very low certainty).
1 finding from 1 review
Cognition and behaviour · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults (aged 16 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).
1 finding from 1 review
Seizure freedom · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
Cognition and behaviour · children (aged 4 months to 16 years) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · children (aged 4 months to 16 years) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Attrition rate · children (aged 4 months to 16 years) with drug‐resistant epilepsy
1 finding from 1 review
Seizure freedom · adults (aged 18 years and over) with drug‐resistant epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · adults (aged 18 years and over) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · adults (aged 18 years and over) with drug‐resistant epilepsy
1 finding from 1 review
Cognition and behaviour · adults (aged 18 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults (aged 18 years and over) with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Attrition rate · adults (aged 18 years and over) with drug‐resistant epilepsy
1 finding from 1 review
Adverse effects · children (aged 1 to 18 years) with drug‐resistant epilepsy
1 finding from 1 review